Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy.

Autor: Şahin AB; Department of Medical Oncology, School of Medicine, Bursa Uludag University, 16059, Gorukle, Nilufer, Bursa, Turkey. absahin@uludag.edu.tr., Cubukcu E; Department of Medical Oncology, School of Medicine, Bursa Uludag University, 16059, Gorukle, Nilufer, Bursa, Turkey., Ocak B; Department of Medical Oncology, School of Medicine, Bursa Uludag University, 16059, Gorukle, Nilufer, Bursa, Turkey., Deligonul A; Department of Medical Oncology, School of Medicine, Bursa Uludag University, 16059, Gorukle, Nilufer, Bursa, Turkey., Oyucu Orhan S; Department of Medical Oncology, School of Medicine, Bursa Uludag University, 16059, Gorukle, Nilufer, Bursa, Turkey., Tolunay S; Department of Pathology, School of Medicine, Bursa Uludag University, Bursa, Turkey., Gokgoz MS; School of Medicine, General Surgery, Bursa Uludag University, Bursa, Turkey., Cetintas S; Department of Radiation Oncology, School of Medicine, Bursa Uludag University, Bursa, Turkey., Yarbas G; Department of Internal Medicine, School of Medicine, Bursa Uludag University, Bursa, Turkey., Senol K; School of Medicine, General Surgery, Bursa Uludag University, Bursa, Turkey., Goktug MR; Department of Internal Medicine, School of Medicine, Bursa Uludag University, Bursa, Turkey., Yanasma ZB; Department of Internal Medicine, School of Medicine, Bursa Uludag University, Bursa, Turkey., Hasanzade U; Department of Internal Medicine, School of Medicine, Bursa Uludag University, Bursa, Turkey., Evrensel T; Department of Medical Oncology, School of Medicine, Bursa Uludag University, 16059, Gorukle, Nilufer, Bursa, Turkey.

Publikováno v: Scientific reports [Sci Rep] 2021 Jul 19; Vol. 11 (1), pp. 14662. Date of Electronic Publication: 2021 Jul 19.